
Loading, please wait...

Loading, please wait...

Managing bipolar disorder across longitudinal treatment cycles presents profound therapeutic challenges for clinicians worldwide. Effective bipolar maintenance pharmacotherapy aims to prevent relapse, sustain euthymia, and minimize long-term neurocognitive decline. However, bridging clinical trial evidence into everyday psychiatric practice remains difficult. International clinical frameworks, such as the Canadian Network for Mood and Anxiety Treatments (CANMAT) recommendations, advocate for mood stabilizers and targeted second-generation antipsychotics as frontline interventions. Nevertheless, real-world observational registries repeatedly document substantial gaps between standardized recommendations and actual clinical prescribing patterns.
Furthermore, patients frequently navigate shifting illness phases, ranging from debilitating depressive episodes to breakthrough hypomania. Consequently, psychiatrists must constantly weigh therapeutic efficacy against tolerability burdens. Acute mood episodes frequently compel clinicians to add secondary medications during destabilization. Unfortunately, practitioners often fail to discontinue these acute adjuncts once remission occurs. Therefore, maintenance regimens often accumulate unnecessary psychotropic agents over time. Recent investigations have sought to determine whether educational initiatives and revised treatment algorithms have improved adherence to global standards. Evaluating contemporary prescribing habits provides vital insight into lingering prescribing pitfalls, enabling physicians to recalibrate their long-term therapeutic decision-making.
A recent multicenter observational study conducted across twenty psychiatric hospitals evaluated maintenance regimens in 323 bipolar disorder patients. The investigators systematically collected prescription records to compare them against established CANMAT guidelines to evaluate real-world consistency. Encouragingly, the overall rate of guideline non-adherence dropped to 12.38 percent, demonstrating marked improvement compared to clinical surveys published in 2014. This positive trend indicates growing clinician familiarity with international standards and evidence-informed mood stabilization strategies.
However, despite these demonstrable gains, notable clinical inconsistencies persist. Inappropriate prescribing primarily involved the improper continuation of antidepressants and suboptimal selection of core mood stabilizers. Specifically, several patients continued antidepressant therapy without sufficient mood stabilizer coverage or received regimens lacking proven prophylactic efficacy. Additionally, clinicians frequently underutilized first-line agents like lithium, favoring complex combinations instead. These departures from established protocols raise meaningful safety concerns. Unopposed or unnecessary antidepressant therapy can destabilize mood rhythms, accelerate rapid cycling, and induce treatment-emergent manic switches. Therefore, while baseline guideline concordance has noticeably advanced, targeted educational interventions must continue to address enduring prescribing anomalies.
Beyond baseline mood stabilizer selection, adjunctive pharmacotherapy represents a dominant feature of contemporary bipolar maintenance. In this cohort, an astounding 67.80 percent of patients received at least one additional medication beyond their primary mood-stabilizing agent. Interestingly, distinct diagnostic subtypes exhibited starkly divergent prescribing patterns. Clinicians prescribed adjunctive antipsychotics most frequently to individuals diagnosed with bipolar I disorder. In contrast, patients with bipolar II disorder received adjunctive antidepressants at significantly higher rates.
This clinical divergence reflects the distinct symptomatic burdens characterizing each illness phenotype. Bipolar I maintenance frequently centers on curbing manic recurrences and severe psychotic features, naturally prompting prolonged second-generation antipsychotic coverage. Conversely, bipolar II disorder is dominated by protracted, recurrent depressive episodes that severely impair psychosocial functioning. As a result, practitioners frequently introduce antidepressants to alleviate persistent low mood. However, clinical guidelines advise significant caution regarding long-term antidepressant maintenance, even in bipolar II presentations. Unless clinicians combine them with robust mood stabilizers like quetiapine or lithium, antidepressants provide questionable prophylactic benefit. Thus, prescribing practices highlight how persistent polarity-specific distress drives distinct adjunctive strategies in outpatient practice.
Complex drug combinations inevitably elevate the risk of psychiatric polypharmacy in routine practice. In the multicenter cohort, 47.10 percent of participants met criteria for polypharmacy during maintenance therapy. Multivariate regression models identified several critical determinants that strongly influenced complex prescribing behaviors. Notably, a history of previous psychiatric hospitalization emerged as an independent predictor of adjunctive therapy and multi-drug regimens. In addition, the polarity and severity of the most recent mood episode significantly influenced treatment complexity.
Furthermore, patient gender played a notable role in shaping adjunctive medication choices. Women frequently received different supplementary agents compared to men, reflecting potential differences in clinical presentation and comorbid anxiety. When patients experience severe, treatment-resistant relapses requiring inpatient stabilization, clinicians aggressively intensify pharmacotherapy to regain behavioral control. Consequently, discharged individuals often remain on these intensive multi-drug regimens indefinitely. Although polypharmacy can successfully resolve acute crisis episodes, prolonged combination therapy creates major clinical challenges. It substantially escalates the risk of drug-drug interactions, metabolic syndrome, organ toxicities, and poor long-term adherence. Therefore, clinicians must identify these high-risk clinical predictors to guide structured medication reconciliation.
These real-world findings underscore crucial lessons for psychiatrists, primary care practitioners, and mental health specialists. First, clinicians should actively audit maintenance regimens to eliminate redundant or hazardous pharmacotherapy. Specifically, practitioners must exercise extreme vigilance when continuing antidepressants during stable euthymic intervals. While acute bipolar depression may occasionally warrant brief antidepressant adjunctive therapy, prolonged use without clear indication invites mood instability. Instead, clinicians should prioritize evidence-based monotherapies or validated combinations such as lithium, quetiapine, or lamotrigine.
Moreover, the widespread reliance on adjunctive medications reveals an urgent need for more nuanced clinical practice guidelines. Traditional guidelines often construct algorithms around monotherapy trials, yet real-world clinical populations frequently present with treatment-resistant symptoms and psychiatric comorbidities. As a result, clinicians inevitably seek personalized combinations to prevent relapse. Future guidelines must therefore provide clear, tiered frameworks for rational polypharmacy, defining when to taper adjuncts safely. In addition, routine therapeutic drug monitoring and metabolic surveillance remain indispensable. By balancing guideline fidelity with patient-centered flexibility, clinicians can minimize medication toxicities while safeguarding long-term affective stability.
Antidepressant monotherapy carries a substantial risk of destabilizing mood in bipolar disorder. Without concurrent mood stabilizers, antidepressants can induce treatment-emergent affective switches into mania or hypomania. Additionally, they may accelerate cycle frequency and trigger mixed states. International clinical guidelines strongly advise against antidepressant monotherapy, recommending evidence-based mood stabilizers or atypical antipsychotics instead.
Psychiatric polypharmacy is primarily driven by illness severity, including a history of psychiatric hospitalizations and the polarity of recent acute episodes. During acute destabilization, clinicians routinely add adjunctive antipsychotics, antidepressants, or sedatives. Unfortunately, practitioners often fail to taper these supplemental agents after achieving remission, resulting in chronic, multi-drug maintenance regimens.
Clinicians should implement structured, periodic medication reviews once patients achieve sustained clinical euthymia. Physicians must carefully evaluate the ongoing indication for acute adjuncts, particularly antidepressants and high-dose sedatives. Tapering should proceed gradually under close symptom monitoring, ensuring that foundational mood stabilizers remain optimized to prevent breakthrough affective episodes.
Disclaimer: This content is for informational and educational purposes only and is not intended as medical advice. Healthcare professionals should exercise clinical judgment and verify details independently. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A multicenter study evaluates guideline concordance and adjunctive medication patterns in bipolar disorder maintenance therapy. While guideline adherence has improved to 87.6%, polypharmacy and inappropriate antidepressant use remain frequent, highlighting the need for individualized, evidence-based regimens.
Today

A landmark study reveals that congenital DLK1 deficiency in women with a history of central precocious puberty causes visceral adiposity, mitochondrial dysfunction, oxidative stress, and neutrophil activation, highlighting the critical need for lifelong cardiometabolic surveillance.
Today

Estetrol (E4), a native fetal estrogen, offers a unique tissue-selective profile with minimal hepatic impact and lower thrombotic risk. This review highlights its clinical use in oral contraception, menopausal symptom management, and emerging applications across oncology and neurology.
Today

Explore revascularisation strategies in dialysis-dependent chronic limb-threatening ischaemia. This review examines surgical bypass vs endovascular therapy, BEST-CLI trial findings, procedural morbidity, conduit availability, and multidisciplinary decision-making for optimal limb salvage.
Today

A recent cross-sectional analysis reveals that over a quarter of randomized controlled trials for non-specific low back pain face discontinuation or unknown status, while more than 36% of completed trials remain unpublished, exposing notable reporting gaps in spine and musculoskeletal clinical research.
Today

This case report examines the longitudinal CBCT evolution of Stage 2 MRONJ in a 70-year-old woman on denosumab at the site of a pre-existing mandibular dense bone island. It emphasizes the radiographic features, differential diagnosis, and multidisciplinary strategies required for high-risk bone lesions.
Today